Alembic releases generic Pradaxa
Dabigatran etexilate capsules are a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.
Alembic is launching dabigatran etexilate capsules 75 mg and 150 mg, which is the generic of Boehringer Ingelheim’s Pradaxa.
Dabigatran etexilate capsules are a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.
Premature discontinuation of dabigatran etexilate capsules increases the risk of thrombotic events, the company noted.
[Read more: Alembic intros generic Perforomist]
Alembic will offer dabigatran etexilate capsules in dosages of 75 mg and 150 mg, in 60-ct. bottles.